New hope drug enters first human tests for tough cancers
NCT ID NCT07358806
Summary
This is the first human study of an experimental drug called OCT-598 for people with advanced solid tumors that have stopped responding to standard treatments. Researchers will test increasing doses to find the safest and most effective amount, both when given alone and when combined with standard chemotherapy. The main goal is to understand how the body handles the drug and what side effects occur, which will help design future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center
RECRUITINGGoyang-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Bundang Hospital (SNUBH)
RECRUITINGSeongnam-si, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.